Status:

COMPLETED

A Pharmacokinetic Study of SHR8554 Injection in the Population With Renal Insufficiency and Healthy Participants

Lead Sponsor:

Jiangsu HengRui Medicine Co., Ltd.

Conditions:

Moderate to Severe Postoperative Pain

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

Brief Summary

The study is being conducted to evaluate the safety and pharmacokinetic characteristics of SHR8554 injection in subjects with renal insufficiency and healthy subjects.

Eligibility Criteria

Inclusion

  • Able and willing to provide a written informed consent;
  • The estimated glomerular filtration rate (eGFR) of subjects in groups must meet the corresponding standards;
  • Male or female;
  • with a body mass index (BMI) between 18.0 and 28.0 kg/m2.

Exclusion

  • History of clinically significant allergies, known allergy to SHR8554, or any other structural analogs;
  • Subjects with positive tests for infectious diseases;
  • Pregnancy or lactation women, or a fertility male or female is not willing to contraception during test;
  • Unable to tolerate venipunctures or have a history of fainting needles and blood;
  • Historic abuse of alcoholic beverages;
  • Smoke ≥ 10 cigarettes per day within 3 months prior to the study;
  • History of drug abuse;
  • Diseases with abnormal clinical manifestations that occurred before screening or are currently occurring and need to be excluded for normal renal function group;
  • Vital signs, physical examination, 12-lead electrocardiogram, or laboratory examination deemed clinically significant by the investigator for normal renal function group;
  • History of renal transplantation and/or requirement for renal dialysis treatment during the study period for severe renal function group;
  • Urinary incontinence or anuria (e.g., \< 100 mL/day) for severe renal function group;
  • Other reasons that the investigator consider it inappropriate to participate in the trial.

Key Trial Info

Start Date :

September 20 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 13 2023

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT07189962

Start Date

September 20 2022

End Date

April 13 2023

Last Update

September 24 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Affiliated Hospital of Qingdao University

Qingdao, Shandong, China, 266003

A Pharmacokinetic Study of SHR8554 Injection in the Population With Renal Insufficiency and Healthy Participants | DecenTrialz